10-K: 3M posts modest growth, exits PFAS output

3M delivered slight sales growth in 2025, lifted margins on an adjusted basis, completed its PFAS manufacturing exit, and advanced major legal settlements while boosting dividends and buybacks.

Summary

• Net sales rose 1.5% to $24.95 billion; organic sales up 0.9% (adjusted organic +2.1%).
• GAAP operating margin was 18.6%; adjusted operating margin improved to 23.4%.
• GAAP EPS was $6.00 (down 17% YoY) driven by legal and other special items; adjusted EPS increased 10% to $8.06.
• Safety & Industrial sales rose 3.9% to $11.38 billion with operating margin at 24.9% (25.4% adjusted).
• Transportation & Electronics sales declined 1.3% to $8.27 billion; PFAS exit weighed on segment; adjusted sales +2.3%.
• Consumer sales slipped 0.2% to $4.92 billion; operating margin expanded to 20.2%.
• Completed exit of PFAS manufacturing by year-end 2025; continuing remediation and asset disposition work.
• Advanced PFAS legal matters: Public Water Suppliers settlement ($10.5–$12.5B, 2024–2036) and proposed New Jersey settlement (up to $450M; $281M charge; $400M expected PV payments).
• Combat Arms Earplugs settlement totals up to $6.0B (2023–2029); accrued $2.4B remaining at 12/31/25 with >99% claimant participation.
• Other environmental liabilities were $7.7B at 12/31/25 (down from $8.6B).
• Cash from operations was $2.31B; capital expenditures $0.91B; 2026 capex guided to ~ $1.1B.
• Share repurchases totaled $3.25B under a new $7.5B authorization (announced Feb 2025) with ~$4.6B remaining at 12/31/25.
• Quarterly dividend was $0.73 in 2025; first-quarter 2026 dividend increased 7% to $0.78.
• Long-term debt (principal) was $12.60B; 2025 new issuance $1.1B; credit ratings: Moody’s A3 (Stable), S&P BBB+ (Stable), Fitch A- (Stable).
• Retained ~15% of Solventum at 12/31/25 (fair value ~$2.0B) after selling ~$0.6B of shares; intends full divestiture within five years of the 2024 spin-off.
• Cybersecurity oversight described; no material incidents reported; ERP transformation and restructuring underway.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a cautiously positive update: adjusted execution improved margins and EPS, PFAS manufacturing exit is complete, and legal settlements progressed; however, sizable long-dated cash outflows and litigation/regulatory risks remain.

Positives

• Adjusted EPS grew 10% to $8.06; adjusted operating margin expanded to 23.4%.
• Safety & Industrial delivered 3.9% sales growth and margin expansion (25.4% adjusted).
• Transportation & Electronics adjusted sales +2.3% after excluding PFAS manufactured products impact.
• Consumer margin improved to 20.2% despite flat-to-down sales.
• Completed exit of PFAS manufacturing by end-2025, reducing long-term operating and reputational risk.
• Shareholder returns: $3.25B repurchases in 2025; quarterly dividend raised to $0.78 (+7%) for Q1 2026.
• Legal overhang progression: PWS settlement approved and underway; CAE settlement >99% participation; other environmental liabilities declined to $7.7B.
• Stable investment-grade ratings (Moody’s A3, S&P BBB+, Fitch A-); ample $4.25B revolver undrawn.
• Working capital improved to $6.79B (from $4.63B) and pensions ~98% funded globally.

Negatives

• GAAP EPS fell 17% YoY to $6.00 due to legal charges and special items.
• Transportation & Electronics reported sales down 1.3% (GAAP) and margin contraction to 17.4% amid PFAS exit headwinds, auto OEM softness and commercial vehicle weakness.
• Consumer segment sales -0.2% with soft discretionary demand and packaging/expression declines.
• Cash from operations of $2.31B constrained by large settlement payments and legal outflows.
• Continued exposure to sizable PFAS- and CAE-related payments and contingencies through 2036.

Risks

• PFAS liabilities, settlements and evolving regulations; PWS settlement of $10.5–$12.5B (2024–2036) and ongoing remediation and litigation (including AFFF MDL).
• Proposed New Jersey PFAS settlement up to $450M (hearing held Jan 7, 2026; ~$400M PV expected payments recorded).
• Combat Arms Earplugs settlement up to $6.0B (2023–2029); potential for additional claims outside settlement scope.
• Spin-off risks related to Solventum: dis-synergies, services and supply agreements, retained PFAS liabilities for certain healthcare products, timing/valuation of stake divestiture.
• Macroeconomic, geopolitical, tariffs and FX volatility affecting global demand and costs (56% of revenue outside U.S.).
• Supply chain, raw-material and energy cost variability; limited- or sole-source suppliers risk.
• Cybersecurity and ERP implementation risks; potential disruptions despite no material incidents to date.
• AI-related risks (accuracy, privacy, IP, evolving regulation) impacting operations and compliance.
• Pension and interest rate risks; credit rating changes could elevate funding costs.
• Legal and regulatory proceedings (product liability, environmental, anti-corruption, government contracts) with potential fines, penalties, and operational limits.

Future Outlook

Focus areas include driving organic growth via commercial excellence and new product introductions, executing the ERP and transformation programs, managing PFAS-related remediation and settlement payments, divesting the remaining Solventum stake within five years of spin, maintaining investment-grade ratings, sustaining dividend growth, and deploying the $7.5B repurchase authorization while targeting ~ $1.1B of capex in 2026.

Management Comments

• Completed the exit of PFAS manufacturing by year-end 2025 and continue to address legacy remediation and asset transitions.
• Delivered adjusted margin expansion through growth, productivity and lower restructuring costs while investing for future growth.
• Advanced resolution of major legal matters, including the PWS and CAE settlements, enhancing visibility on long-term cash outflows.
• Raised the dividend and continued sizable share repurchases under a new $7.5B authorization.

Industry Context

StockSavvy.ai notes diversified industrial peers continue to navigate uneven global demand, supply-chain normalization, tariffs and FX. Industrial conglomerates with portfolio focus and legal clarity have outperformed. 3M’s adjusted margins in the low-20s align with high-quality peers, but its PFAS and CAE settlements create an overhang atypical versus Honeywell, GE Aerospace, and Emerson. The completed PFAS manufacturing exit and settlement progress move 3M closer to the cleaner balance sheets of peers, while segment trends (auto OEM, electronics, consumer discretionary) mirror broader industry softness.

Comparison to Industry Standards

• Profitability: 3M’s 2025 adjusted operating margin of 23.4% is competitive with leading multi-industry peers that typically post high-teens to low-20s operating margins (e.g., Honeywell segment margins historically in the low-20s).
• Growth: Adjusted organic growth of ~2.1% trails high-growth industrial tech peers (e.g., automation/software-exposed portfolios) but is in line with diversified peers exposed to automotive and electronics cycles.
• Balance sheet and ratings: Investment-grade ratings (A3/BBB+/A-) are comparable to large-cap peers; ongoing litigation liabilities are higher than typical industry levels, weighing on flexibility.
• Capital returns: A 7% dividend increase and $3.25B buybacks are consistent with shareholder-return profiles of mature industrials, though legal outflows constrain aggregate FCF conversion versus best-in-class.
• Portfolio actions: The Solventum spin-off and PFAS manufacturing exit align with the sector trend toward portfolio simplification (e.g., recent spin-offs/divestitures across industrial conglomerates).

Management Changes

Corporate Governance

Legal Proceedings

• PFAS Public Water Suppliers (PWS) settlement approved (March 2024); total payments $10.5–$12.5B from 2024 through 2036; $8.2B aggregate paid on PWS and CAE through 12/31/25.
• Proposed New Jersey PFAS settlement up to $450M; $281M pre-tax charge recorded in 2Q25; court hearing held January 7, 2026.
• Combat Arms Earplugs settlement up to $6.0B (2023–2029); >99% participation; accrued $2.4B remaining at 12/31/25.
• Respirator mask/asbestos matters: accruals (excluding Aearo) of $473M at 12/31/25 for liabilities and defense costs.
• Other environmental liabilities: $7.7B recorded at 12/31/25, majority PFAS-related; ongoing AFFF MDL activity (~15,200 cases per JPML as of Jan 2026).

Related Party Transactions

• Solventum separation agreements: transition services, distribution, contract manufacturing, supply and cross-licensing; ~ $150M net transition services income in 2025 and ~$50M in 2024; amounts due from/to Solventum at 12/31/25 were ~$0.4B and ~$0.1B, respectively.

Stakeholder Impact

• Shareholders: Adjusted earnings and margin expansion; dividend increased 7% and robust buybacks executed under new $7.5B authorization.
• Employees: Transformation and restructuring programs continue; new supply chain leadership role created.
• Customers: PFAS manufacturing exit requires product transitions/substitutions in certain applications; service continuity supported via Solventum transition agreements.
• Communities/Regulators: Ongoing PFAS remediation and settlement payments; New Jersey and other regulatory engagements continue.
• Creditors: Stable investment-grade ratings maintained; $1.1B of new debt issued and $1.8B repaid; undrawn $4.25B revolver.
• Pensioners: Global pension plans ~98% funded at year-end 2025.

Next Steps

• Execute ~$1.1B 2026 capex focused on growth, productivity and sustainability.
• Continue ERP and transformation programs, including restructuring actions.
• Progress PFAS remediation, settlement payments (PWS through 2036; CAE through 2029), and New Jersey settlement approval process.
• Manage Solventum transition services and supply agreements; evaluate timing of further stake sales within five-year window.
• Maintain investment-grade ratings and opportunistically deploy remaining $4.6B buyback authorization.

Key Dates

Recommendation

Progress on PFAS manufacturing exit, settlement execution, adjusted margin/EPS gains, and increased capital returns are balanced by sizable long-dated legal cash outflows, continued litigation uncertainty, and mixed demand in key end-markets; maintaining a Hold pending greater visibility on residual PFAS risks, cash generation, and Solventum stake monetization.

Keywords

3M, PFAS, Combat Arms Earplugs, Solventum, Safety & Industrial, Transportation & Electronics, Consumer, Adjusted EPS, Share repurchase, Dividend, New Jersey settlement, Public Water Suppliers settlement, AFFF MDL, Spin-off, Litigation, ERP, Cybersecurity, Pensions, Credit ratings